<DOC>
	<DOC>NCT00978224</DOC>
	<brief_summary>The purpose of the study is to determine whether Viusid administration improves malnutrition, atherosclerosis, erythropoietin response and the frequency of infection episodes in subjects with Chronic Inflammatory Syndrome under hemodialysis treatment. The duration of this double-blind placebo controlled phase 3 clinical trial will be 60 weeks. All patients enrolled in the study will be receiving the standard treatment for Chronic Inflammatory Syndrome including hemodialysis and administration of a hypercaloric and hyperproteic diet. Efficacy assessment will be carried out 12 weeks after the end of Viusid or placebo treatment.</brief_summary>
	<brief_title>Viusid Administration in Subjects With Chronic Inflammatory Syndrome Under Hemodialysis Treatment</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<criteria>Subjects with chronic terminal nephropathy under hemodialysis treatment for at least 3 months Signed informed consent Patients with chronic terminal nephropathy previously treated with peritoneal dialysis Receptors of a renal graft Patients with malignant neoplastic conditions Pregnant women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>dietary supplement</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>Chronic Inflammatory Syndrome</keyword>
	<keyword>Viusid</keyword>
</DOC>